Vor Biopharma (VOR) Research & Development (2020 - 2026)
Vor Biopharma (VOR) reported Research & Development of $17.6 million for Q1 2026, down 34.1% year-over-year from $26.7 million in Q1 2025, and down 8.31% on a QoQ basis from $19.2 million in Q4 2025.
Vor Biopharma (VOR) has 7 years of Research & Development data on file, last reported at $17.6 million in Q1 2026.
- Quarterly Research & Development fell 34.1% year-over-year to $17.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $312.4 million (up 226.5% YoY) and the FY2025 annual result came in at $321.5 million, up 244.58% from the prior year.
- Research & Development declined to $17.6 million in Q1 2026 per VOR's latest filing, from $19.2 million in the prior quarter.
- Across five years, Research & Development topped out at $261.5 million in Q2 2025 and bottomed at $14.1 million in Q3 2025.
- The 5-year median for Research & Development is $21.8 million (2024), against an average of $34.8 million.
- Peak annual rise in Research & Development reached 1098.27% in 2025, while the deepest fall reached 35.18% in 2025.
- Tracing VOR's Research & Development over 5 years: stood at $17.1 million in 2022, then advanced by 22.48% to $20.9 million in 2023, then increased by 21.3% to $25.3 million in 2024, then declined by 24.29% to $19.2 million in 2025, then dropped by 8.31% to $17.6 million in 2026.
- Per Business Quant, the three latest VOR Research & Development figures stand at $17.6 million (Q1 2026), $19.2 million (Q4 2025), and $14.1 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 626,092.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 4.32 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -101.30 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 1.46 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 961.60 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -2.30 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 1.54 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 364.87 Mn |
| 10 | Vor Biopharma | 628.83 Mn | 628.83 Mn | - | 17.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 17.60 Mn |
| Dec 31, 2025 | 19.19 Mn |
| Sep 30, 2025 | 14.14 Mn |
| Jun 30, 2025 | 261.50 Mn |
| Mar 31, 2025 | 26.70 Mn |
| Dec 31, 2024 | 25.35 Mn |
| Sep 30, 2024 | 21.82 Mn |
| Jun 30, 2024 | 21.82 Mn |
| Mar 31, 2024 | 24.32 Mn |
| Dec 31, 2023 | 20.90 Mn |
| Sep 30, 2023 | 27.61 Mn |
| Jun 30, 2023 | 23.90 Mn |
| Mar 31, 2023 | 21.92 Mn |
| Dec 31, 2022 | 17.06 Mn |
| Sep 30, 2022 | 16.88 Mn |
| Jun 30, 2022 | 15.33 Mn |
| Mar 31, 2022 | 15.28 Mn |
| Dec 31, 2021 | 12.69 Mn |
| Sep 30, 2021 | 12.93 Mn |
| Jun 30, 2021 | 12.97 Mn |
| Mar 31, 2021 | 8.94 Mn |
| Dec 31, 2020 | 11.33 Mn |
| Sep 30, 2020 | 8.14 Mn |
| Jun 30, 2020 | 5.98 Mn |
| Mar 31, 2020 | 6.17 Mn |